{
    "SPADE_N_14050": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_N_14050",
            "Peptide Name": "Ranatuerin-2-AW D4K, D19K, K20L (R2AW analog, Synthetic AMPs, XXA, UCLL1c)",
            "Source": "sequence truncation, Amino acid substitution, animal-derived, natural derivative",
            "Family": "Not found",
            "Gene": "Not found",
            "Sequence": "GFMKTAKNVAKNVAATLLKLLK",
            "Sequence Length": 22,
            "UniProt Entry": "Ref",
            "Protein Existence": "Not found",
            "Biological Activity": [
                "Anti-Gram+",
                "Anti-Gram-",
                "Anti-MRSA",
                "Antibiofilm",
                "Anticancer"
            ],
            "Target Organism": "Not found",
            "Hemolytic Activity": "Not found",
            "Cytotoxicity": "Not found",
            "Binding Target": "Not found",
            "Linear/Cyclic": "Not found",
            "N-terminal Modification": "Not found",
            "C-terminal Modification": "Not found",
            "Stereochemistry": "Not found",
            "Structure Description": "Not found",
            "Formula": "Not found",
            "Mass": 2359.91,
            "PI": 10.6,
            "Hydrophobicity": 0.33,
            "Half Life": "Not found",
            "Function": "Not found",
            "Literature": [
                {
                    "Author": "Yao A, Liu T, Cai Y, Zhou S, Chen X, Zhou M, Ma C, Chen T, Shaw C, Wang L2023",
                    "Reference": "Antibiotics (Basel). 2023 Dec 19;13(1):5. doi: 10.3390/antibiotics13010005.PubMed",
                    "Title": "Progressive Design of a Ranatuerin-2 Peptide from Amolops wuyiensis: Enhancement of Bioactivity and In Vivo Efficacy."
                }
            ],
            "Frequent Amino Acids": "KAL",
            "Absent Amino Acids": "CDEHIOPQRSUWY",
            "Basic Residues": 5,
            "Acidic Residues": 0,
            "Hydrophobic Residues": 12,
            "Polar Residues": 15,
            "Positive Residues": 5,
            "Negative Residues": 0,
            "Net Charge": 5,
            "Comments": "Sequence analysis: APD analysis reveals that this sequence is similar (68.97%) toranatuerin-2-AWK: 23%; L=A: 18%. GRAVY: 0.327; mol Wt: 2359.933; mol formula: C108H193N27O27S1; mol ex coeff: 0.Activity: S. aureus NCTC 10788 or MRSA (MIC 2 uM), E. coli ATCC 8739 (MIC 2 uM), K. pneumoniae ATCC 43816 (MIC 4 uM), E. faecium NTCC 12697 (MIC 4 uM), and P. aeruginosa ATCC 9027 (MIC 8 uM). Good at biofilm inhibition but poor at eradication. Effective against multiple cancer cell lines (IC50 3.671-12.40 uM).Toxicity: horse RBC: low hemo.lytic (HC50> 128 uM).MOA:bacteria: Showed membrane permeabilization: E. coli, S. aureus, and P. aeruginosa.Structure: became helical in 50% TFE.Animal model:wax moth: 10 mg/kg peptide is not toxic (no death). It protected animals by increasing their survival from 2 days (no treatment) to 5 days (5 mg/kg) to more than 5 days (10 mg/kg).",
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_UN_26832",
                    "Similarity": 1.0,
                    "Sequence": "GFMKTAKNVAKNVAATLLKLLK"
                },
                {
                    "SPADE_ID": "SPADE_N_05862",
                    "Similarity": 1.0,
                    "Sequence": "KLLKHKLLVTLA"
                },
                {
                    "SPADE_ID": "SPADE_N_09624",
                    "Similarity": 1.0,
                    "Sequence": "LKLLKLL"
                }
            ]
        }
    }
}